Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands

Journal of Medical Economics
Marieke HeisenMaarten J Postma

Abstract

Until recently, standard treatment of venous thromboembolism (VTE) concerned a combination of short-term low-molecular-weight heparin (LMWH) and long-term vitamin-K antagonist (VKA). Risk of bleeding and the requirement for regular anticoagulation monitoring are, however, limiting their use. Rivaroxaban is a novel oral anticoagulant associated with a significantly lower risk of major bleeds (hazard ratio = 0.54, 95% confidence interval = 0.37-0.79) compared to LMWH/VKA therapy, and does not require regular anticoagulation monitoring. To evaluate the health economic consequences of treating acute VTE patients with rivaroxaban compared to treatment with LMWH/VKA, viewed from the Dutch societal perspective. A life-time Markov model was populated with the findings of the EINSTEIN phase III clinical trial to analyze cost-effectiveness of rivaroxaban therapy in treatment and prevention of VTE from a Dutch societal perspective. Primary model outcomes were total and incremental quality-adjusted life years (QALYs), as well as life expectancy and costs. Over a patient's lifetime, rivaroxaban was shown to be dominant, with health gains of 0.047 QALYs and cost savings of €304 compared to LMWH/VKA therapy. Dominance was robustly present in ...Continue Reading

References

Jan 1, 1997·Journal of the American Medical Informatics Association : JAMIA·L A Lenert, R M Soetikno
May 19, 2001·Journal of Health Services Research & Policy·A RobinsonM Eccles
Jan 22, 2003·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Joseph A CapriniAlexander T Cohen
May 28, 2004·The New England Journal of Medicine·Vittorio PengoUNKNOWN Thromboembolic Pulmonary Hypertension Study Group
Apr 22, 2005·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
May 25, 2005·Archives of Internal Medicine·Susan R KahnIan Shrier
Jun 1, 2005·The American Journal of Medicine·Drahomir AujeskyMark S Roberts
Aug 19, 2007·Drugs & Aging·Harald E VonkemanMart A F J van de Laar
Oct 17, 2007·Thrombosis and Haemostasis·Alexander T CohenUNKNOWN VTE Impact Assessment Group in Europe (VITAE)
Feb 23, 2008·American Journal of Respiratory and Critical Care Medicine·Robin CondliffeJoanna Pepke-Zaba
Feb 26, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·John A Heit
Sep 5, 2008·The European Respiratory Journal·D M MeadsJ Pepke-Zaba
Oct 2, 2009·Journal of Thrombosis and Haemostasis : JTH·A J Ten Cate-HoekM A Joore
Jun 1, 2006·Expert Review of Pharmacoeconomics & Outcomes Research·Antonio Gómez-OutesPaolo Prandoni
Jul 2, 2010·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Lisa EricsonIngela Björholt
Aug 21, 2010·Journal of Thrombosis and Haemostasis : JTH·L LinkinsC Kearon
Oct 5, 2010·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Geert-Jan GeersingUNKNOWN AMUSE Study Group
Nov 19, 2010·Cost Effectiveness and Resource Allocation : C/E·Stefan A BaetenLouis W Niessen
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Jan 13, 2011·Journal of Medical Economics·Andras RuppertMichael Lees
Feb 22, 2011·The Journal of Thoracic and Cardiovascular Surgery·Eckhard MayerPhilippe Dartevelle
Mar 23, 2011·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Patrick W SullivanVahram Ghushchyan
Jun 8, 2011·Journal of Thrombosis and Haemostasis : JTH·W ZondagUNKNOWN Hestia Study Investigators
Jul 8, 2011·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Thalia S Field, Michael D Hill
Mar 28, 2012·The New England Journal of Medicine·Harry R BüllerAnnelise Segers
Sep 1, 2014·European Heart Journal·Stavros V KonstantinidesUNKNOWN Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
Sep 3, 2014·European Heart Journal·Stavros Konstantinides, Adam Torbicki
Nov 20, 2014·Acta Médica Portuguesa·Isabel Fonseca SantosIsmini Chatzitheofilou

❮ Previous
Next ❯

Citations

Apr 5, 2019·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Ira L LeedsBashar Safar
Jan 29, 2021·Cardiovascular Therapeutics·Muhammad AjmalTom Lassar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.